Ethris GmbH has raised $26.3 million in a Series B financing round to support development of messenger RNA (mRNA) therapeutics, an area of growing interest to the pharmaceutical industry. The Munich, Germany-based company has developed a technology enabling the delivery of candidate therapies directly to the respiratory system. Whereas the small number of approved RNA medicines are delivered to patients by injection, Ethris has developed nebulisation technologies for inhaled administration.
